SPX announces completion of Anhydro acquisition

SPX Corporation (NYSE: SPW) today announced that it has completed the acquisition of the Anhydro business, a Soeborg, Denmark-based global supplier of liquid concentration equipment, powder processing solutions, and dewatering plants and equipment.  The terms of the transaction were not disclosed.

Anhydro supplies a wide range of evaporation and drying solutions for dairy, food, and starch producers and for the chemical and pharmaceutical industries worldwide.  The transaction includes all Anhydro's business units with the exception of its Danish Filter business, Simatek A/S, and its German, U.K. and U.S. operations, as well as certain individual projects. The acquired business units employ 225 employees and are expected to generate 2010 full-year revenue of approximately 85 million Euros.

"The addition of Anhydro broadens our technology equipment offerings and systems capabilities and strengthens our ability to serve customers in the global food, pharmaceutical and chemical processing end markets," said SPX Chairman, President and Chief Executive Officer Christopher J. Kearney. "This strategic transaction also builds on our recent acquisition of Gerstenberg Schroder and underscores our commitment to expanding our Flow Technology segment, which remains a key component of our global growth strategy."

SPX first announced that it had entered into a definitive agreement to acquire Anhydro on June 18, 2010.  Anhydro will operate within SPX's Flow Technology segment.

Posted in:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scaling organ‑chip technology for human‑relevant drug discovery